This trial is active, not recruiting.

Condition macular degeneration
Treatment rheopheresis blood filtration
Phase phase 3
Sponsor OccuLogix
Start date August 1999
End date December 2005
Trial size 180 participants
Trial identifier NCT00078221, AMD-02-99


AMD is a progressive disease of the retina which is nourished by a network of tiny blood vessels. There is evidence to suggest that the flow of nutrients to the retina is impaired in patients with AMD. Rheopheresis blood filtration uses blood filters that deplete excesses of large proteins, fats and other substances from the blood, improving blood flow to the macula, potentially improving vision.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking double-blind
Primary purpose treatment

Eligibility Criteria

Male or female participants from 50 years up to 85 years old.

- Age 50-85 - Diagnosis of Dry AMD - BCVA between 20/32 and 20/125 in at least one eye - Numerous large plaques (soft drusen) - No history of HIV, Hepatitis B or C - Elevation of certain blood factors, such as total cholesterol, fibrinogen, and IgA

Trial information was received from ClinicalTrials.gov and was last updated in May 2008.
Information provided to ClinicalTrials.gov by OccuLogix.